Regentis Biomaterials Ltd. (RGNT)
NYSE American · Healthcare · Medical Instruments & Supplies
$1.67−9.73%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $11.7M
- 52-week range
- $1.23 – $15.50
- 52-week change
- −75.33%
- EPS (trailing)
- −$2.46
Fiscal year to Dec 2025
- Net income
- −$13.6M
- Diluted EPS
- −$24.16
From the company’s annual report on SEC EDGAR.
About Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
Headquarters: Herzliya, Israel · regentis.co.il